• Made in China 2025 identified the healthcare sector as a key focus for more local procurement.

• Huge reduction seen in imports of mid- to high-end medical devices, with some categories falling by up to 20%.

• Multinationals must either further invest in China factories, or pursue an acquisition strategy to ensure they have the necessary local production capability, or pursue a mix of both.

• If a multinational already has its own major operations in China it is likely to have more leverage and buy-in from head office to invest in its own plant.

About InterChina

InterChina is a leading strategy and corporate finance boutique specialized in China. Healthcare is one of our core sectors of expertise with consultants and advisors dedicated to the space. Our multinational and Chinese clients choose to work with us because we provide real understanding, deliver practical results, and know how to get things done. We are a partner led firm and distinguish ourselves by the deep level of engagement partners have in client engagements.

Rick Woo
Principal, InterChina
Rick.Woo@InterChinaConsulting.com